CaaMTech is a psychedelic drug research company that aims to develop novel tryptamines through fundamental scientific research.
CaaMTech
In September 2021, CaaMTech announced the completion of a $22 million Series A financing round, led by Noetic Fund.
“CaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.”
Preventing bad trips is one of their stated goals (see the Vice article below). The focus here is on ‘aeruginascin’ which is one of the lesser known tryptamines in magic mushrooms.
Key Staff
- Andrew Chadeayne – Founder & CEO
- Davis Wuolle – Technology & Marketing
- Jon Cooper – Board Member
News
- Patent Combining Psychedelics With Cannabinoids Allowed by USPTO (press release, February 2021)
- Scientists are Trying to Redesign Magic Mushrooms so You Never Have a Bad Trip (Vice, March 2020)
Activities
B2B
B2C
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Noetic Fund II Leads Series A Financing into CaaMTech Inc. (Press Release, 08 September 2021)Noetic, through its second fund, has invested the majority of CaaMTech's $22 million Series A funding round. The money will be used to move into clinical trials.